FDA Approves NUZYRA — Paratek Pharmaceuticals, Inc.

On October 2, 2018, Paratek Pharmaceuticals received FDA approval for NUZYRA (omadacycline), an oral antibiotic poised to address treatment gaps caused by the rising threat of drug-resistant gram-negative bacteria, though market share remains largely dependent on long-term commercial success against established competitors.